Why a cannabis business is betting on dogs to reach FDA approval

The pursuit of FDA approval by Endovia for its cannabinoid drug targeting canine cancer and chronic pain is a strategic move that highlights the potential of the companion-animal market for cannabis businesses. By focusing on veterinary approval, Endovia is able to navigate the complex regulatory landscape surrounding cannabis products for human use. This approach allows the company to leverage the growing demand for alternative treatments in the animal health industry, which is a significant and largely untapped market.

The decision by Endovia to target the companion-animal market is also noteworthy because it underscores the growing recognition of the therapeutic potential of cannabinoids in veterinary medicine. As the cannabis industry continues to evolve, companies are exploring new avenues for growth and development, including the use of cannabinoids in animal health products. This trend is likely to continue, with other companies following Endovia's lead and pursuing FDA approval for veterinary cannabis products. The success of Endovia's efforts could pave the way for further research and development in this area.

As Endovia moves forward with its FDA approval process, industry watchers will be keenly interested in the outcome. A successful approval would not only validate the company's approach but also provide a potential roadmap for other cannabis businesses looking to enter the veterinary market. It will be important to monitor the progress of Endovia's application and the broader trends in the companion-animal market, as these developments could have significant implications for the future of the cannabis industry and its expansion into new and innovative areas.

Originally reported by mjbizdaily.com. HempNews adds analysis for cannabis & hemp readers.